Download the whole Issue
ORIGINAL RESEARCH
Atypical cases of silicosis in clinical practice. Berkheeva Z.M., Pugacheva O.A., Safina K.R. P.16
REVIEWS
Epidemiology of sarcoidosis in the Russian Federation. Vizel A.A., Vizel I.Yu., Amirov N.B. P.66
MEDICIN’S HISTORY
HELP FOR PRACTITIONER
___
THE STATUS OF HYPOTHALAMIC-PITUITARY-ADRENAL-OVARIAN SYSTEM AND FUNCTIONAL ACTIVITY OF THE THYROID GLAND IN WOMEN WITH HYPERANDROGENISM AND HYPERPROLACTINEMIA
UDC 618.17:616.43
DOI: 10.20969/VSKM.2017.10(5).7-11
AKHUNDOVA NATAVAN E., C. Med. Sci., associate professor of the Department of obstetrics and gynecology of Azerbaijan Medical University, Republic of Azerbaijan, AZ 1022, Baku, Gasimzade str., 14, e-mail: mic_amu@mail.ru
Abstract. Aim. Our objective was to study the features of hormone changes in hypothalamic-pituitary-ovarian adrenal systems in patients with hyperandrogenism and hyperprolactinemia. Material and methods. 68 women with the hyperandrogenism and hyperprolactinemia were examined. 27 (29,7%) of them were diagnosed with simple form, while 41 (60,3%) of them had mixed hyperprolactinemic form. The simple form of intracellular pituitary adenoma has been manifested by hyperpolactinemia (25,9%), the syndrome of «empty» sella turcica (7,4%), symptomatic medication (14,8%) and idiopathic hyperprolactinemia (51,81%). Polycystic ovary syndrome with insulin resistance (29,3%) and without insulin resistance (17%), primary hypothyroidism (14,63%), hyperthyroidism (4,9%), hypogonadotropic hypogonadism (4,9%), hypergonadotropnyc hypogonadism (7,3%), ovarian tumors (4,8%), and obesity (17%) were seen in patients with the mixed form. The study determined serum levels of follicle-stimulating hormone, luteinizing hormone, thyroid stimulating hormone, estrone, estradiol, total testosterone, 17-oxiprogesterone, dehidroèpiandron sulfate, free thyrpxine, free thyroxine, antimûllerian hormone and sex hormone-binding globulin before and after integrated pathogenetic therapy. Results and discussion. It was found that patients with hyperandrogenism and hyperprolactinemia present the levels of luteinizing hormone [(12,37±0,89) mIU/ml], the ratio of luteinizing to follicule-stimulating hormone (2,03±0,16), 17-oxiprogesteron [(1,0±0,08) ng/ml], testosterone [(1,13±0,07) ng/ml], androstenedione [(3,28±0,12) ng/ ml], dehydroepiandrosterone sulfate [(3,11±0,26) ng/ml], that re ect dysfunctional activity of the hypothalamic-pituitary- ovarian adrenal integrated system. Conclusion. Complex pathogenetic therapy of patients with hyperandrogenism and hyperprolaktinemia reduces the levels of these hormones and increases the levels of estradiol [(79,03±1,56) ng/ ml] free thyroxine [(1,9±0,03) ng/dl] and sex hormone binding globulin [(58,34±1,57) nmol/l].
Key words: hyperprolactinemia, hyperandrogeniâ, hypothalamic-pituitary-adrenal-ovarian system, pituitary-thyroid system.
For reference: Akhundova NE. The status of hypothalamic-pituitary-adrenal-ovarian system and functional activity of the thyroid gland in women with hyperandrogenism and hyperprolactinemia. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 7—11. DOI: 10.20969/VSKM.2017.10(5).7-11.
REFERENCES
1. Bode D. Hirsutism in Women. Am Fam Physician. 2012; 85 (4): 373-380.
2. Blume-Peytavi U, Atkin S, Shapiro J. Skin Academy; European Consensus on the evaluation of women presenting with excessive hair growth. Eur J Dermatol. 2009; 19 (6): 597-602.
3. Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol. 2008; 68 (5): 800-805.
4. Martin KA, Chang RJ, Ehrmann DA. Evaluation and treatment of hirsutism in premenopausal women: an Endockine Society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93 (4): 1105-1120.
5. Yıldız BO, Bolour S, Woods K, Moore A, Azziz R. Visualy scoring hirsutism. Hum Reprod Update. 2010; 16 (1): 51-64.
6. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009; 88 (1): 32-45.
7. Brown J, Farquhar C, Lee O, Thoomath R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009; 2: 121-135.
8. Hasani-Ranjbar S, Vahidi H, Taslimi S, Karimi N, Larijani B. A systematic review on the ef cacy of herbal medicines in the management of human drug-induced hyperprolactinemia; potential sources for the development of novel drugs. Int J of Pharmacology. 2010; 6: 691-695.
9. Xianbin L, Yilang T, Chuanyue W. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolac- tinemia: meta-analysis of randomized controlled. PLoS One. 2013; 8 (8): 70179.
10. Agarwal M, Das A, Singh SS. Hyperprolactinemia with normal serum prolactin: Its clinical signi cance. J Hum Reprod Sci. 2010; 3 (2): 111-112.
11. Litvak EO. Sovremennye podhody k lecheniju sindroma giperprolaktinemii [Modern approaches to the treatment of the syndrome of hyperprolactinemia]. Jendokrinologija [Endocrinology]. 2012; 3 (1): 5-12.
UDC 617.586-002.44-02:616.379-008.64
DOI: 10.20969/VSKM.2017.10(5).12-15
BATURIN VLADIMIR A., D. Med. Sci., professor, Head of the Department of clinical pharmacology of Stavropol State Medical University, Russia, 355000, Stavropol, Mir str., 310, e-mail: prof.baturin@gmail.com
BOLATCHIEV ALBERTD., postgraduate student of the Department of clinical pharmacology of Stavropol State Medical University, Russia, 355000, Stavropol, Mir str., 310, e-mail: bolatalbert@gmail.com
ZINCHENKO OLEG V., C. Med. Sci., associate professor of the Department of anesthesiology, resuscitation and emergency of Stavropol State Medical University, Russia, 355000, Stavropol, Mir str., 310, e-mail: regionar2008@yandex.ru
BATURINA MARIA V., C. Med. Sci., associate professor of the Department of clinical pharmacology of Stavropol State Medical University, Russia, 355000, Stavropol, Mir str., 310, e-mail: nimdark@mail.ru
KUNITSINA ELENA A., bacteriologist of Center of Clinical Pharmacology and Pharmacotherapy, Russia, 355042, Stavropol, 50 let VLKSM str., 50/2, e-mail: kynavi@mail.ru
Abstract. Aim. The changes in constitution of microorganisms in diabetic foot syndrome have been studied. The difference in their sensitivity to antibacterial drugs over the past 10 years has been assessed. Material and methods. The study was performed on patients with diagnosis: «Type 2 diabetes complicated with diabetic foot syndrome». Biological material was sampled from ulcerative necrotic lesions on the feet when examining patients followed by bacteriological study. 55 patients were examined in 2006 and 748 patients — in 2016. Results and discussion. In 2006 the microorganisms isolated from the wound were dominated by Enterobacteriaceae spp. and Staphylococcus spp. In 2016 it was still dominated by Enterobacteriaceae spp. and Staphylococcus spp. However, there were found Enterococcus spp. (18,9% from the number of gram-positive microorganisms) as well as P. aeruginosa (11,5% from the total number of isolated gram-negative bacteria). In 2006 the proportion of methicillin-resistant S. aureus (MRSA) was 31%. Resistance of Enterobacteriaceae spp. To the 3rd-generation of cephalosporin (cefotaxime) was 37%, and to imipenem/meropenem was 7%. In 2016 the proportion of MRSA was 42,5%. In 2016 a high resistance of Enterobacteriaceae spp. To the 3rd-generation of cephalosporin (cefotaxime — 63,5% and imipenem/meropenem — 43,5% was revealed). Conclusion. Over the past 10 years there has been a clear tendency of increase in proportion of MRSA in diabetic patients with diabetic foot syndrome. The number of Enterobacteriaceae spp., which is producer of extended-spectrum beta-lactamases, including microorganisms resistant to carbapenems, has increased signi cantly among gram-negative microorganisms.
Key words: diabetic foot syndrome, resistance, antibiotic sensitivity, diabetes mellitus, MRSA.
For reference: Baturin VA, Bolatchiev AD, Zinchenko OV, Baturina MV, Kunicina EA. Change in microorganism sensitivity to antibacterial agents in patients with diabetic foot syndrome over the past 10 years. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 12—15. DOI: 10.20969/VSKM.2017.10(5).12-15.
REFERENCES
1. IDF Diabetes Atlas Group. IDF Diabetes Atlas Group Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract. 2015; 109 (3): 461–465.
2. Park TH, Anand A. Management of diabetic foot: Brief synopsis for busy orthopedist. J Clin Orthop trauma. 2015; 6 (1): 24–29.
3. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103 (2): 137–149.
4. Baturin VA, Shchetinin YeV, Demidenko IF, Korableva OA. Byulleten antibiotikorezistentnosti respiratornykh patogenov v OITAR goroda Stavropolya [Bulletin of antibiotic resistance of respiratory pathogens in the Stavropol City Hospital’s Intensive Care Department]. Stavropol: StGMU. 2014; 24 p.
5. Strachunskogo LS, Belousov YuB, Kozlov SN ed. Prak- ticheskoye rukovodstvo po antiinfektsionnoy khimioterapiii [Practical guidance on anti-infectious chemotherapy]. Smolensk: MAKMAKh. 2007; 464 p.
6. Yakovleva SV ed. Ratsionalnaya antimikrobnaya terapiya [Rational antimicrobial therapy: a guide for practicing doctors]. Moskva [Moscow]: Litterra. 2015, 1040 p.
7. Zubkov MN. Sbor, transportirovka biologicheskogo mate- riala i traktovka rezul’tatov mikrobiologicheskih issledovanij [Collection, transportation of biological material and inter- pretation of the results of microbiological studies]. Klin- icheskaya mikrobiologiya i antimikrobnaya himioterapiya [Clinical microbiology and antimicrobial chemotherapy]. 2004; 2: 143-154.
8. Semin NA, Sidorenko SV, Rezvan SP et al, ed. Opredelenie chuvstvitel’nosti mikroorganizmov k antibakterial’nym preparatam (Metodicheskie ukazaniya MUK 4.2.1890-04) [Determination of the sensitivity of microorganisms to antibacterial drugs (Methodologi- cal guidelines MUK 4.2.1890-04)]. Klinicheskaya mi- krobiologiya i antimikrobnaya himioterapiya [Clinical microbiology and antimicrobial chemotherapy]. 2004; 4: 306-357.
ATYPICAL CASES OF SILICOSIS IN CLINICAL PRACTICE
UDC 616.24-003.662-057(470.41)
DOI: 10.20969/VSKM.2017.10(5).16-22
BERKHEEVA ZUKHRA M., C. Med. Sci., associate professor of the Department of preventative medicine of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, е-mail: kgmu_profpat@mail.ru
PUGACHEVA OLGA A., physician of Republican Occupational Pathology Center, Russia, 420036, Kazan, Lechebnaya str., 7, e-mail: olya.ar2011@mail.ru
SAFINA KADRIYA R., Head of Republican Occupational Pathology Center, Russia, 420036, Kazan, Lechebnaya str., 7, e-mail: kadriya-safina@mail.ru
Abstract. For many years the leading place in the structure of occupational diseases of respiratory organs has been occupied by pneumoconiosis. The well-known type of the disease caused by the effects of quartz dust is silicosis. In recent years, pulmonary disorders seen in workers exposed to industrial aerosols clinically and radiologically maintained as typical picture of silicosis. Aim. The cases of silicosis among sandblast cleaners of glass products have been described. Material and methods. Analysis of the structure of occupational diseases in the Republic of Tatarstan according to the register of the Republican Center of occupational pathology for 2012--2016 years has been performed. 1 135 cases of occupational diseases have been studied. Results and discussion. Respiratory disorders have been ranked 2nd in the structure of occupational diseases for many years, exceeding the prevalence in Russia by 11,9%. The main diseases of respiratory system are chronic bronchitis and pneumoconiosis. There has been a gradual decrease in proportion of pneumoconiosis and an increase in the incidence of chronic bronchitis. The article contains extracts from the case reports of patients with silicosis. Conclusion. Analysis of the incidence of silicosis in sandblasting glass cleaners reveals late diagnosis of the disease, which is related to the lack of x-ray screening on periodic health examinations. Given observations indicate changes in respiratory system of the workers due to the impact of industrial aerosols. Clinical manifestations of pulmonary disease develop within a short work experience with quartzy dust (about 4 years). Radiological changes were characterized by diffuse lung brosis and polymorphism of nodular and interstitial shadows.
Key words: occupational respiratory diseases, pneumoconiosis, silicosis.
For reference: Berheeva ZM, Pugacheva OA, Sa na KR. Atypical cases of silicosis in clinical practice. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 16—22. DOI: 10.20969/VSKM.2017.10(5).16-22.
REFERENCES
1. Ljubchenko PN, Stashuk GA, Terpigorev SA, Atamanchuk AA, Massarygin VV. Sluchai netipichnyh legochnyh zabolevanij pri vozdejstvii promyshlennyh ajerozolej [Cases of atypical lung diseases when exposed to industrial aerosols]. Medicina truda [Medicine of labor]. 2014; 10: 31-35.
2. Pljuhin AE, Burmistrova TB, Postnikova LV, Kovaleva AS. Pnevmokoniozy v uslovijah sovremennyh promyshlennyh proizvodstv [Pneumoconiosis in conditions of modern industrial production]. Medicina truda [Medicine of labor]. 2013; 7: 22-27.
3. Upravlenie Federal’noj sluzhby po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka [Department of the Federal service for supervision of consumer rights protection and human well-being]. O sostojanii sanitarno- jepidemiologicheskogo blagopoluchija naselenija v Respublike Tatarstan v 2014 godu: gosudarstvennyj doklad [On the status of sanitary-epidemiological welfare of the population in the Republic of Tatarstan in the year 2014: state report]. Kazan. 2016; 328 p.
4. Federal’naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka [Federal service for supervision of consumer rights protection and human well-being]. O sostojanii sanitarno-jepidemiologicheskogo blagopoluchija naselenija v Rossijskoj Federacii v 2014 godu: gosudarstvennyj doklad [On the status of sanitary- epidemiological welfare of the population in the Russian Federation in the year 2014: state report]. Moskva [Moscow]. 2016; 200 p.
5. Berheeva ZM, Ginijatova AM. Mnogoletnjaja dinamika i struktura professional’noj zabolevaemosti v Respublike Ta- tarstan [Long-term dynamics and structure of occupational morbidity in the Republic of Tatarstan]. Vestnik sovremen- noj klinicheskoj medicina [The Bulletin of Contemporary Clinical Medicine]. 2015; 8 (1): 10-17.
6. Osipov SA, Malysheva IJu, Berheeva ZM. Proshloe i nastojashhee profpatologicheskoj sluzhby v Respublike Tatarstan [The past and present of the pathological service in the Republic of Tatarstan]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of Contemporary Clinical Medicine]. 2015; 8 (1): 82-86.
MODERN MORBIDITY TRENDS FROM PROSTATE DISORDERS IN POPULATION OF MOSCOW
UDC 616.65-036.22(470-25)
DOI: 10.20969/VSKM.2017.10(5).23-29
GEVORKYAN ASHOT R., C. Med. Sci., Head of the Department urology of City Outpatient Clinic No 195, Russia, 121355, Moscow, Krylatskie holmi str., 51, e-mail: ashot_gevorkyan@mail.ru
BERSENEVA EVGENIA A., D. Med. Sci., Head of the Department of higher and additional professional education of N.A. Semashko Federal State Research Institute of Public Health, Russia, Moscow, Vorontzovo Pole str., 12-1, tel. +7-916-216-84-59, e-mail: eaberseneva@gmail.com
Abstract. Aim. Primary morbidity and prevalence of prostate disorders and cancer in population of Moscow in 2006—2015 have been studied in comparison with the Russian Federation. Material and methods. The trends of the incidence and prevalence of prostatic diseases and cancer in population of Moscow, as compared to the Russian Federation, have been analyzed in the article, based on the of cial statistical reports for 2006—2015. Results and discussion. Diseases of the prostate gland constitute the largest proportion of all urological diseases in the structure of morbidity and prevalence of the diseases of the genitourinary system in Moscow. It was shown that the trends in the incidence and prevalence of prostate diseases among residents of the capital do not match the characteristics of dynamics of similar indicators in the Russian Federation, which might be related to the lack of diagnosis and deterioration in organization of dispensary monitoring of these patients in Moscow. It has been established that prostate gland is the most frequent substrate for malignant tumors in the structure of all oncological diseases revealed in inhabitants of the capital. Prostate cancer is also the most frequent cause of death. Among all oncological diseases the highest rate of increase in the incidence rate (by 33,6%) and mortality (by 14,6%) during 2006—2015 was seen in patients with prostate cancer. The effectiveness of targeted oncological examinations, the timeliness of prostate cancer detection and the effectiveness of treatment in Moscow are higher than in the Russian Federation as a whole. However, even in the capital, the indicators of active and timely prostate cancer detection are inadequate for modern medical care. As a result, almost a third (29,7%) of the cases of prostate cancer is detected on the III—IV stage of the disease in Moscow. Conclusion. The results of the study indicate the need to improve urological care for the population, including the outpatient stage. Completeness and timeliness of diagnosis, and therefore the effectiveness of treatment of prostate disorders and cancer depend rst and foremost on its function.
Key words: morbidity, prevalence, prostate diseases, prostate cancer, timeliness of diagnosis, Moscow.
For reference: Gevorkyan AR, Berseneva EA. Modern morbidity trends from prostate disorders in population of Moscow. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 23—29. DOI: 10.20969/VSKM.2017.10(5).23-29.
REFERENCES
1. Apolikhin OI, Sivkov AV, Beshliev DA, Solntseva TV, Komarova VA. Analiz uronefrologicheskoj zabolevaemosti v Rossijskoj Federacii za desjatiletnij period (2002-2012 godah) po dannym o cial’noj statistiki [The analysis of uronephrosiological morbidity in the Russian Federation for a ten-year period (2002-2012) according to of cial statistics]. Jeksperimental’naja i klinicheskaja urologija [Eksperimental’naya i klinicheskaya urologiya]. 2014; 2: 4–12.
2. Apolikhin OI, Sivkov AV, Solntseva ТV. Invalidnost’ vsled- stvie zabolevanij mochepolovoj sistemy v Rossijskoj Federacii po dannym o cial’noj statistiki [Disability due to diseases of the genitourinary system in the Russian Fed- eration according to of cial statistics]. Jeksperimental’naja i klinicheskaja urologija [ Experimental and clinical urology]. 2012; 1: 37-46.
3. Glybochko PV. Rossijskaja urologija v XXI veke [Russian urology in the XXI century]. Urologija [Urology]. 2015; 5: 4-9.
4. Maksimov VA, Pushkar DY, Umarov MS. Sovremennyj vzgljad na problemu skrininga raka predstatel’noj zhelezy [The modern view on the problem of cancer screening of the prostate gland]. Urology [Urology]. 2009. (5): 74-77.
5. Prezidium RAN [Presidium of the Russian Academy of Sciences]. Fundamental’nye issledovanija i innovacii v prakticheskoj urologii [Fundamental research and innovations in practical urology]. Materialy portala «Nauchnaja Rossija» [Materials of the portal «Scienti c Russia»]. 2016; access mode https://scienti crussia.ru/ articles/prezidium-ran-fundamentalnye-issledovaniya-i- innovatsii-v-prakticheskoj-urologii
6. Loran OB. Fundamental’nye issledovaniya i innovatsii v prakticheskoy urologii [Fundamental Research and Inno- vation in Practical Urology]. Moscow. 2016; Available at: http: //scienti crussia. ru/articles/ prezidium-ran-fundamen- talnye-issledovaniya-i-innovatsii-v-prakticheskoj-urologii.
7. Kaprin AD, Starinsky VV, Petrov GV. Sostoyanie onkologicheskoi pomoshchi naseleniy Russia v 2013 godu [The state of oncological assistance to the population of Russia in 2013]. Moscow: FGBU «MNIOI imeni P.A. Gercena [MCRI them. PA Herzen]; 2013; 232 p.\
MOLECULAR INTERRELATION OF VASCULAR REMODELING IN PATIENTS WITH OSTEOARTHRITIS AND ARTERIAL HYPERTENSION
UDC 616.728.3-002:616.12-008.331.1
DOI: 10.20969/VSKM.2017.10(5).29-35
KABALYK MAXIM A., C. Med. Sci., assistant of professor of Institute of therapy and instrumental diagnostics of Pacific State Medical University, Russia, 690002, Vladivostok, Ostryakov Ave., 2, e-mail: maxi_maxim@mail.ru
Abstract. Aim. Interrelation between vascular remodeling and factors of cell differentiation, proliferation and apoptosis in patients with osteoarthritis and arterial hypertension has been studied. Material and methods. The study was performed on 65 patients with osteoarthritis of knee joints, including 58 women and 7 men aged (66,7±7,9) years with duration of the disease 1—18 years. Comparison group included 40 patients with arterial hypertension without osteoarthritis at the age of (63,8±6,5) years. 18 patients without arterial hypertension and osteoarthritis at the age of (59,6±8,3) years, comparable to the main group by gender and age, were included in control group. All patients were assessed on the joint status using visual analogue pain scale, WOMAC questionnaire; the thickness of the intima-media complex has been measured on the common carotid artery. Plasma GDF-5 (growth and differentiation factor 5), Fas (apoptosis-related factor) and OSGIN-1 (oxidative stress-inducing growth inhibitor 1) have been determined. Results and discussion. The highest Fas level was seen in osteoarthritis group of patients, who showed statistically signi cant difference with the group of arterial hypertension patients without osteoarthritis and with control. The concentration of OSGIN-1 was signi cantly higher in the group of patients with osteoarthritis and arterial hypertension compared to control and did not show signi cant difference between the groups of hypertensive patients. The level of GDF-5 was signi cantly higher in the osteoarthritis group compared to the group of patients with arterial hypertension without osteoarthritis and to control. The study of the history of osteoarthritis and arterial hypertension revealed duration of osteoarthritis of (7,08±3,13) years, arterial hypertension — (15,53±5,56) years. The history of hypertension before the debut of osteoarthritis in this group of patients was in average (8,45±2,43) years. The maximal pain level according to the visual analogue scale and WOMAC was observed in patients with osteoarthritis with intima-media complex thickness of common carotid artery of more than 1,1 mm, which was signi cantly higher in comparison with patients with intima-media complex of less than 0,9 mm. Conclusion. The degree of vascular remodeling is associated with clinical manifestations of osteoarthritis. Imbalanced regulation of cell cycle and apoptosis is observed in patients with osteoarthritis and arterial hypertension, reaching its maximum in comorbidity. Vascular remodeling within the cardiovascular continuum with arterial hypertension and osteoarthritis has close pathogenetic interrelations on molecular level, including via regulation of the cell cycle.
Key words: arterial hypertension, osteoarthritis, vascular remodeling, GDF-5, OSGIN-1.
For reference: Kabalyk MA. Molecular interaction of vascular remodeling in patients with osteoarthritis and arterial hypertension. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 29—35. DOI: 10.20969/ VSKM.2017.10(5).29-35.
REFERENCES
1. Kabalyk MA. Kliniko-patogeneticheskoe znachenie belkov teplovogo shoka s massoj 70 i 27 kDa pri osteoartrite [The clinical and pathogenetic signi cance of 70- and 27-kDa heat shock proteins in osteoarthritis]. Nauchno- prakticheskaja revmatologija [Rheumatology Science and Practice]. 2017; 55 (2): 187-191. doi: 10.14412/1995-4484- 2017-187-191.
2. Dubikov AI, Kabalyk MA, Koreckaja TJu. Mikrokrsital- licheskij stress v patogeneze osteoartroza [Microcrystal- line stress in the pathogenesis of osteoarthritis]. Terape- vticheskij arhiv [Therapeutic Archives]. 2016; 88 (5): 32-36. doi: 10.17116/terarkh201688532-36.
3. Haara MM, Manninen P, Kroger H, Arokoski JP, Karkkainen A, Knekt P. Osteoarthritis of nger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis. 2003; 62: 151–158.
4. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003; 139: 330-336.
5. Kabalyk MA. Osobennosti citokinovogo statusa u bol’nyh osteoartritom i arterial’noj gipertoniej [Features cytokine status in patients with osteoarthritis and hypertension]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of Contemporary Clinical Medicine]. 2017; 10 (3): 10-15. doi: 10.20969/VSKM.2017.10(3).10-15.
6. Gotsman I. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severi-ty of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008; 10 (7): 494–498.
7. Imamura M, Targino RA, Hsing WT, Imamura S, Azevedo RS, Boas LS, Tozetto-Mendoza TR, Al eri FM, Filippo TR, Battistella LR. Concentration of cytokines in patients with osteoarthritis of the knee and bromyalgia. Clin Interv Aging. 2014; 9: 939-944. doi: 10.2147/CIA.S60330.
8. Musumeci G, Castrogiovanni P, Trovato FM, Weinberg AM, Al-Wasiyah MK, Alqahtani MH, Mobasheri A. Biomarkers of Chondrocyte Apoptosis and Autophagy in Osteoarthritis. Int J Mol Sci. 2015; 16 (9): 20560-20575. doi: 10.3390/ ijms160920560.
9. Guimarães DA, Rizzi E, Ceron CS, Martins-Oliveira A, Gerlach RF, Shiva S, Tanus-Santos JE. Atorvastatin and sildena l decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension. Redox Biol. 2015; 6: 386-95. doi: 10.1016/j.redox.2015.08.017
10. Kabalyk MA. Biomarkery i uchastniki remodelirovanija subhondral’noj kosti pri osteoartroze [Biomarkers and participants in the remodeling of the subchondral bone in osteoarthritis]. Tihookeanskij medicinskij zhurnal [Paci c Medical Journal]. 2017; 1: 36-41. doi: 10.17238/PmJ1609- 1175.2017.1.37-41.
11. Brennan MS, Matos MF, Richter KE, Li B, Scannevin RH. The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes. Sci Rep. 2017; 7: 42054. doi: 10.1038/srep42054.
12. Dubikov AI, Belogolovyh LA, Medved’ EJe. Rol’ apoptoza v patogeneze revmatoidnogo artrita i osteoartroza [The role of apoptosis in the pathogenesis of rheumatoid arthritis and osteoarthritis]. Nauchno-prakticheskaja revmatologija [Scienti c and Practical Rheumatology]. 2005; 1: 64- 68.
13. Lu XL, Zhao CH, Yao XL, Zhang H. Quercetin attenuates high fructose feeding-induced atherosclerosis by suppress- ing in ammation and apoptosis via ROS-regulated PI3K/ AKT signaling pathway. Biomed Pharmacother. 2017; 85: 658-671. doi: 10.1016/j.biopha.2016.11.077.
14. Alexander TH, Sage AB, Chen AC, Schumacher BL, Shelton E, Masuda K, Sah RL, Watson D. Insulin-like growth factor-I and growth differentiation factor-5 promote the formation of tissue-engineered human nasal septal cartilage. Tissue Eng Part C Methods. 2010; 16 (5): 1213- 1221. doi: 10.1089/ten.TEC.2009.0396.
15. Yang X, Shang H, Katz A, Li X. A modi ed aggregate culture for chondrogenesis of human adipose-derived stem cells genetically modi ed with growth and differentiation factor 5. Biores Open Access. 2013; 2 (4): 258-265. doi: 10.1089/biores.2013.0014.
16. Enomoto H, Inoki I, Komiya K. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol. 2003; 162: 171-181.
17. Koskinen A, Vuolteenaho K, Nieminen R, et al. Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP- 1 and MMP-3 in synovial uid from OA patients. Clinical and Experimental Rheumatology. 2011; 29 (1): 57– 64.
18. Kabalyk MA. Rol’ sosudistyh faktorov v patogeneze os- teoartrita [The role of vascular factors in the pathogenesis of osteoarthritis]. Sovremennye problemy nauki i obra- zovanija [Modern problems of science and education]. 2017; 2: 50.
19. Wu R, Wang W, Huang G, Mao X, Chen Y, Tang Q, Liao L. Endothelin-1 induces oncostatin M expression in osteoarthritis osteoblasts by trans-activating the oncostatin M gene promoter via Ets-1. Mol Med Rep. 2016; 13 (4): 3559-3566. doi:10.3892/mmr.2016.4960.
ANDROGEN STATUS AND CLINICAL CHARATERISTICS OF STABLE ANGINA IN MALES
UDC 616.12-009.7-055.1:616.681-008.64:616.43
DOI: 10.20969/VSKM.2017.10(5).35-40
NAUMOV ALEXANDER S., C. Med. Sci., associate professor of the Department of internal medicine of E.A. Wagner Perm State Medical University, Russia, 614990, Perm, Petropavlovskaya str., 26, tel. +7-904-849-74-49, e-mail: san280208@yandex.ru
KARPUNINA NATALIA S., D. Med. Sci., associate professor of the Department of internal medicine of E.A. Wagner Perm State Medical University, Russia, 614990, Perm, Petropavlovskaya str., 26, tel. +7-902-831-24-12, e-mail: karpuninapsma@mail.ru
NAUMOV SERGEI A., C. Med. Sci. Chief physician of Clinical Cardiological Health Centre, Russia, 614990, Perm, Sibirskaya str., 84, tel. +7-902-832-62-04, e-mail: san280208@yandex.ru
Abstract. Aim. The features and severity of gonadotropin and androgen dysfunction in patients with all functional classes of stable angina were studied. Material and methods.145 patients with stable angina and 26 healthy volunteers without any features of coronary heart disease have been monitored. All of them were males comparable by age. The levels of gonadotropin and testosterone have been measured in blood and fractionated 17-ketosteroids (androsterone, dehydroepiandrosterone, etiocholanolone) in 24-hour urine samples in all groups. Statistics included comparable analysis. Results and discussion. The 1st stages of the disease were characterized by signi cant functional changes in pituitary — sex glands system with increasing levels of hormones depending on androgenic activity. Furthermore, while the disease has been progressing, the androgen-secreting function of sex glands decreased progrediently. 3 major types of hormonal disorders have been suggested: 1) normal androgen level with the trend of increasing luteinizing and follicle-stimulating hormone levels; 2) increase of luteinizing and follicle-stimulating hormone and the trend of androgen level lowering; 3) increase of luteinizing and follicle-stimulating hormone with low level of androgens. These features of hormone secretion have in uenced clinical conditions of patients with stable angina with maximal interaction in the 3rd type of disorder. Conclusion. The investigation has showed variable disorders in hypothalamus—pituitary—sex glands system in young and middle-aged males with stable angina. It seems expedient to evaluate androgen status in addition to the routine laboratory check-up in such patients. Detection of androgen de ciency should be considered as objective of medical treatment in order to achieve better life quality of patients with III—IV functional class of angina.
Key words: stable angina, males, gonadotropins, androgens.
For reference: Naumov AS, Karpunina NS, Naumov SA. Androgen status and clinical characteristics of stable angina in males. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 35—40. DOI: 10.20969/VSKM.2017.10(5).35-40.
REFERENCES
1. Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009; 40: 1082-1090.
2. Barrett-Connor E. Why women have less heart disease than men and how diabetes modi es women’s usual cardiac protection. Global Heart. 2013; 8: 95-104.
3. Go A, Mozaffarian D, Roger V. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014; 129: 399-410.
4. Sharvadze GG, Kurbatov DG, Poddubskaya EA et al. Androgen-de citnoe sostoyanie i serdechno-sosudistiye zabolevania: aktualniye voprosi komorbidnosti v klinicheskoy praktike [Androgen de ciency and cardiovas- cular diseases: acute problems of co-morbidity in clinical practice]. Racionalnaya Farmacoterapia v Kardiologii [Rational Pharmacotherapy in Cardiology]. 2010; 6: 532- 538.
5. Ukkola O, Huttunen T, Puurunen VP et al. Total testoster- one levels, metabolic parameters, cardiac remodeling and exercise capacity in coronary artery disease patients with different stages of glucose tolerance. Annals of Medicine. 2013; 45: 206–212.
6. Morgunov LYu. De cit androgenov i associirovannaya s nim patologiya v obtchesomaticheskoi practike [Androgen de ciency and associated pathology in general practice]. Internet resource: http://www.mif-ua.com/archive/ article/13292
7. Halimov YuSh, Shustov SB, Frolov DS. Vozrastnoi androgenniy de cit kak factor riska kardiovaskulyarnoi patologii [Age-associated androgen de ciency as a risk factor of cardiovascular pathology]. Endocrinologia: novosti, mneniya, obucheniye [Endocrinology: news, opinions, studying]. 2013; 1: 67–74.
8. Allameh F, Pourmand G, Bozorgi A et al. The Association between Androgenic Hormone Levels and the Risk of Developing Coronary Artery Disease (CAD). Iran Journal of Public Health. 2016; 1: 14–19.
9. Bu Beng Yeap. Sex steroids and cardiovascular disease. Asian Journal of Andrology. 2014; 16: 239–247.
10. Vertkin AL, Morgunov LYu, Naumov AV et al. Deficit androgenov i associirovannaya s nim obtchesomatiches- kaya patologiya [Androgen de ciency and associated general pathology]. Farmateka [Pharmateca]. 2008; 9: 27– 33.
ONCOLOGICAL INCIDENCE IN OIL-PRODUCING REGIONS OF THE REPUBLIC OF TATARSTAN: LONG-TERM EPIDEMIOLOGICAL ANALYSIS
UDC 616-006-036.22(470.41)
DOI: 10.20969/VSKM.2017.10(3).40-46
PETROV ILIA V., postgraduate student of the Department of hygiene and occupational medicine of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 9, tel. +7-987-187-56-44, e-mail: ilia.v.petrov@mail.ru, ORCHID ID: http://orcid.org/0000-0002-2097-5679
Abstract. Aim. The aim of the study is analysis of dynamics of primary growth incidence and prevalence on the territory of oil-producing regions in the Republic of Tatarstan for the period of 2005—2014. Material and methods. Analysis of of cial statistical information «Statistics of population health and health care (based on materials of Tatarstan Republic)» for 2005—2014, was performed. The data on primary tumor incidence and prevalence in children (0—14 years) as well as in the whole population of oil-producing areas was processed. The method of direct standardization was applied. Con dence intervals were calculated (con dence probability 0,95). Results and discussion. Over the studied period an adverse trend of increasing primary growth incidence was revealed. Mean annual index of primary incidence in the studied area (10,5 per 1000; CI 9,7—11,3) is higher than the average in Tatarstan (9,8 per 1,000; CI 9,4—10,2), but this difference was not statistically signi cant (p>0,05). Mean annual index of primary tumor incidence in children on the territory of oil production is lower than in the whole Republic, which is 2,6 per 1000 (CI 2,2—2,97) and 3,4 per 1000 (CI 2,95—3,85), respectively, but the difference was not statistically signi cant (p>0,05). Both in the overall republic and on the territory of oil-producing regions a trend of signi cant increase in the incidence of tumors among general population was noted. There was statistically signi cant difference between the areas of oil extraction and the whole Republic. At the same time the incidence of tumors among children was signi cantly higher than the national average in Leninogorsk and Aznakaevo districts (p=0,05). Conclusion. For the period of 2005—2014 the adverse trend of increasing primary growth incidence and prevalence both in the whole Republic and on the territory of oil-producing areas was revealed. Compared to 2004, in 2014 the primary incidence in the areas of oil production has increased on 1,35%, while in Tatarstan — 1,16 times. In general, within the studied area, the primary growth incidence and prevalence among the whole population was not signi cantly different from the average national indicators. At the same time the areas where the rates of primary growth incidence and prevalence exceeded average indicators in Tatarstan were revealed. The incidence of tumor compared to Tatarstan in general is signi cantly higher in Bavlinsky municipal district. The results indicate the need for further in-depth analysis of existing risk factors on the territory of several oil-producing areas.
Key words: oncologic disease, incidence, growth prevalence, malignant tumors, oil production.
For reference: Petrov I.V. Oncological incidence in oil-producing regions of the Republic of Tatarstan: long-term epidemiological analysis. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (3): 40—46. DOI: 10.20969/ VSKM.2017.10(3).40-46.
REFERENCES
1. Neinfekcionnye zabolevanija [Non-communicable di- seases]. Informacionnyj bjulleten’ VOZ [WHO Newsletter]. 2015; 355: www.who.int/mediacentre/factsheets/fs355/ru
2. Kaprin AD, Starinskii VV, Petrova GV ed. Zlokachestven- nye novoobrazovanija v Rossii v 2015 godu (zabolevae- most’ i smertnost’) [Malignant neoplasms in Russia in 2015 (morbidity and mortality)]. Moskva [Moscow]: MNIOI imeni PA Gercena — lial FGBU «NMIRC» Minzdrava Rossii [Moscow Oncology research Institute named after P. A. Herzen, branch of fgbu «NERC» Ministry of health of Russia]. 2017; 250 p.
3. O roli pervichnoy pro laktiki raka v bor’be so zlokachest- vennymi novoobrazovaniyami. Informatsionno-metod- icheskoye pis’mo Rospotrebnadzora No01 / 8981-1-34 ot 18 iyulya 2011 goda: Pervichnaya pro laktika raka v usloviyakh sovremennoy Rossii: Sbornik informatsionno- metodicheskikh pisem [On the role of primary cancer pre- vention in the ght against malignant neoplasms. Informa- tional and methodological letter of Rospotrebnadzor No01 / 8981-1-34 dated July 18, 2011: Primary cancer prevention in modern Russia: Collection of information-methodical let- ters]. Moskva: Federal’nyy tsentr gigiyeny i epidemiologii Rospotrebnadzora [Moscow: Federal center of hygiene and epidemiology of Rospotrebnadzor]. 2011; 88 p. http:// www.gostrf.com/normadata/1/4293799/4293799626.htm
4. Hasanov RSh, Shakirov KT, Gabitova SE et al. Vtorichnaja pro laktika novoobrazovanij v sisteme onkologicheskoj po- moshhi naseleniju Respubliki Tatarstan [Secondary preven- tion of tumors in the system of the oncological help to the population of the Republic of Tatarstan]. Povolzhskij onkol- ogicheskij vestnik [Volga Cancer Gazette]. 2014; 2: 51-59.
5. Biktemirova RG, Gataullin IG, Miheeva GH. Jekologiches- kaja situacija kak factor riska formirovanija onkologiches- koj zabolevaemosti v Respublike Tatarstan [Ecological situation as a risk factor for oncological morbidity in the Republic of Tatarstan]. Vektor nauki Tol’jattinskogo gosu- darstvennogo universiteta [Vector Science Togliatti State University]. 2012; 1: 23-25.
6. Fomina SV, Stepanova NV, Svjatova NV. Regional’nye osobennosti zabolevaemosti zhitelej Respubliki Tatarstan [Morbidity regional features of the Tatarstan Republic residents]. Fundamental’nye issledovanija [Fundamental research]. 2013; 12 (2): 350-355.
7. Valeeva JeR, Stepanova NV, Kamalova FM et al. Zakonomernosti formirovanija zabolevaemosti i smertnosti naselenija ot zlokachestvennyh novoobrazovanij v Respublike Tatarstan [The regularities of development of cancer morbidity and mortality rate of the population in the Republic of Tatarstan]. Gigiena i sanitarija [Hygiene and sanitation]. 2015; 9: 9-12.
8. Korobicyn BA, Kuklov AA, Manzhurov IL et al. Ocenka ushherba ot sokrashhenija ozhidaemoj prodolzhitel’nosti zhizni v rezul’tate onkologicheskih zabolevanij [Assessment of damage from reduction of expected ufespan due to cancer]. Jekonomika regiona [Economy of the region]. 2013; 3 (35): 257-264.
THE PREVALENCE OF COMORBIDITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE NORTH-WEST REGION OF RUSSIA BASED OF THE CROSS-SECTIONAL POPULATION STUDY
UDC 616.24-036.12-06-036.22(470.1/.2)
DOI: 10.20969/VSKM.2017.10(5).46-51
POKHAZNIKOVA MARINA A., C. Med. Sci., associate professor of the Department of family medicine of I.I. Mechnikov North-Western State Medical University, Russia, 191015, St. Petersburg, Kirochnaya str., 41, e-mail: pokmar@mail.ru ANDREEVA ELENA A., C. Med. Sci., associate professor of the Department of family medicine of Northern State Medical University, Russia, 163000, Arkhangelsk, Troitsky Ave., 51, e-mail: klmn.69@mail.ru
OVAKIMYAN KARINA V., assistant of professor of the Department of family medicine of I.I. Mechnikov North-Western State Medical University, Russia, 191015, St. Petersburg, Kirochnaya str., 41
MOISEEVA IRINA E., C. Med. Sci., associate professor of the Department of family medicine of I.I. Mechnikov North-Western State Medical University, Russia, 191015, St. Petersburg, Kirochnaya str., 41
LEBEDEV ANATOLIY K., C. Med. Sci., of the Department of family medicine of I.I. Mechnikov North-Western State Medical University, Russia, 191015, St. Petersburg, Kirochnaya str., 41
KUZNETSOVA OLGA YU., D. Med. Sci., professor, Head of the Department of family medicine of I.I. Mechnikov North-Western State Medical University, Russia, 191015, St. Petersburg, Kirochnaya str., 41
DEGRYSE J.-M., D. Med. Sci., professor of the Department of family medicine of Institute of Health and Society Universit Catholique de Louvain, Clos Chapelle-aux-Champs 30, BE–1200 Brussels (Belgium)
Abstract. Aim. The prevalence of comorbidity in patients with chronic obstructive pulmonary disease has been assessed. Air ow obstruction risk factors and their relationship with comorbidity in adults have been identi ed. Matherial and methods. The research was conducted in 2012—2013 in the framework of cross-sectional population based RESPECT study performed in St. Petersburg and Arkhangelsk. Design: cross-sectional study of a random sample of people aged between 35 and 70 years old, attached to the of ces of general practice in 10 clinics in St. Petersburg and 5 clinics in Arkhangelsk. Chronic obstructive pulmonary disease was de ned as FEV1/FVC<0,7 after bronchodilator administration. Results and discussion. 2,388 respondents who lled all questionnaires and demonstrated satisfactory criteria on spirometry test after bronchodilator have been assessed. 37,7% of the participants with post-bronchodilator air ow obstruction reported some respiratory diseases. Comorbidity was more frequently reported by participants with air ow obstruction than by those without one (67,3% vs. 56,3%, respectively). The prevalence of arterial hypertension and myocardial infarction has been reported signi cantly lower in participants without air ow obstruction. The risk of air ow obstruction in patients with arterial hypertension or myocardial infarction was associated with smoking (p<0,001). In patients with arterial hypertension the risk of air ow obstruction was signi cantly higher in men (p<0,001). Participants with air ow obstruction more often than those without one indicated chronic cough in their family members (15,5% vs. 9,7%; p<0,05). There was no signi cant difference in the prevalence of any other respiratory diseases in family history between participants with and without air ow obstruction. Conclusion. The prevalence and structure of comorbidity in patients with chronic obstructive pulmonary disease in residents of the North-West region of Russia and the relationship between risk factors for air ow obstruction and cardiovascular diseases have been established.
Key words: chronic obstructive pulmonary disease, epidemiological study, spirometry, obstructive ventilation disorder, comorbidity.
For reference: Рokhaznikova MA, Andreeva EA, Ovakimyan KV, Moiseeva IE, Lebedev AK, Kuznetsova OYu, Degryse J-M. The prevalence of comorbidity in patients with chronic obstructive pulmonary disease in the North-West region of Russia based of the cross-sectional population study. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 46—51. DOI: 10.20969/VSKM.2017.10(5).46-51.
REFERENCES
1. Global strategy for diagnosis, management and prevention of COPD. Available at: http://www.goldcopd.org. (last updated 2017; last accessed 29.06.2017)
2. Ajsanov ZR, Avdeev SN, Arhipov VV, Belevskij AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. Nacional’nye klinicheskie rekomendacii po diagnostike i lecheniyu HOBL: algoritm prinyatiya klinicheskih reshenij [Federal clinical guidelines on diagnostic and treatement of Chronic Obstructive Pulmonary Disease: the algorithm for making clinical decisions]. Pul’monologija [Pulmonology]. 2017; 27 (1): 13–21.
3. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015; 36 (4): 575-91.
4. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015; 7 (10): 95-109.
5. Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 155–161.
6. Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017; 67 (658): e321-e328
7. Lugtenberg M, Burgers JS, Clancy C, Westert GP, Schneider EC. Current guidelines have limited applicability to patients with comorbid conditions: A systematic analysis of evidence-based guidelines. PloS One. 2011; 6 (10): e25987.
8. Andreeva E, Pokhaznikova M, Lebedev A, Moiseeva I, Kozlov A, Kuznetsova O, Degryse J-M. The RESPECT study: RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related etiology: a study protocol. BMC Public Health. 2015; doi:10.1186/s12889-015- 2161-z.
9. Andreeva E, Pokhaznikova M, Lebedev A, Moiseeva I, Kuznetsova O, Degryse JM. The Prevalence of Chronic Obstructive Pulmonary Disease by the Global Lung Initiative Equations in North-Western Russia. Respiration. 2016; 91 (1): doi:10.1159/000442887.
ANALYSIS OF HOSPITAL MORBIDITY OF THE POPULATION OF OMSK AS A RESULT OF ACUTE POISONING AND EFFECTS OF TOXIC SUBSTANCES FOR 2010-2016
UDC 616-099-036.1-082.4(571.13-25)
DOI: 10.20969/VSKM.2017.10(5).52-55
SABAEV ALEXANDER V., C. Med. Sci., Head of the Department of acute poisoning (in psychiatric patients) of City Clinical Emergency Hospital No 1, Russia, 644112, Omsk, Pereleta str., 9, e-mail alesabaev@yandex.ru
Abstract. Aim. The objective of the study is to analyze dynamics of hospital morbidity of the population of Omsk as a result of acute poisoning and effects of toxic substances for 2010—2016. Material and methods. The data has been obtained from consolidated accounting records of the Department of acute poisonings. Mathematical processing of the material has been performed in recalculation per 100 thousand representatives of relevant population. Traditional methods of extensive and intensive indicators and the average error rate calculation, as well as the Student t-test for signi cance of difference indicator, have been applied. Results and discussion. For the period from 2010 to 2016 there was a statistically signi cant reduction in hospital morbidity of the population of Omsk as a result of acute poisoning or effects of toxic substances by 7,4%. Hospitalization rates among males were signi cantly higher (in average 3,3 times) than among the female population. Signi cant changes in toxicological situation have manifested as a reliable increase in the number of poisonings from synthetic psychoactive substances, with a simultaneous statistically signi cant decrease in the level of hospital morbidity of the population with alcohol, drug, medication toxic effect, corrosive poison, pesticide, industrial or other poisons. Conclusion. The data on the dynamics of the level of hospital morbidity of the population as a result of acute poisoning and effects of toxic substances in the city of Omsk for the period from 2010 to 2016 allow to identify the landmarks of organization in the context of medical care for victims of such condition, as well as the directions of preventive work in the eld of chemical safety of the population.
Key words: acute poisoning, exposure to toxic substances, hospitalized morbidity.
For reference: Sabaev AV. Analysis of hospital morbidity of the population of Omsk as a result of acute poisoning and effects of toxic substances for 2010—2016. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 52—55. DOI: 10.20969/VSKM.2017.10(5).52-55.
REFERENCES
1. Shchepina OP, Medika VА ed. Zdorov’e naseleniya regiona i prioritety zdravoohraneniya [Health of the population of the region and health priorities]. Moskva: GEHOTAR- Media [Moscow: GEOTAR-Media]. 2010; 384 p.
2. Starodubova VI et al, ed. Obshchestvennoe zdorov’e i zdravoohranenie: nacional’noe rukovodstvo [Public health and public health. National leadership]. Moskva: GEHOTAR-Media [Moscow: GEOTAR-Media]. 2014; 624 p.
3. Medik VA, Osipov AM. Obshchestvennoe zdorov’e i zdravoohranenie: mediko-sociologicheskij analiz [Public health and health: medical and sociological analysis]. Moskva [Moscow]: RIOR, INFRA-M. 2012; 358 p.
4. Luzhnikova EA ed. Medicinskaya toksikologiya: nacional’noe rukovodstvo [Medical toxicology: national leadership]. Moskva: GEHOTAR-Media [Moscow: GEOTAR-Media]. 2012; 928 p.
5. Ostapenko YuN et al. Toksikologicheskaya pomoshch’ naseleniyu Rossijskoj Federacii: sostoyanie problem [Toxicological assistance to the population of the Russian Federation: the state of the problem]. Toksikologicheskij vestnik [Toxicological Herald]. 2014; 3 (126): 2-8.
UDC 616.24-036.12-057:613.632.4/.633
DOI: 10.20969/VSKM.2017.10(5).56-65
SHPAGINA LUBOV A., D. Med. Sci., professor, Head of the Department of internal medicine and medical rehabilitation of Novosibirsk State Medical University, Russia, 630084, Novosibirsk, Polzunov str., 21, tel. +7(383)279-99-45, e-mail: mkb-2@yandex.ru
KOTOVA OLGA S., C. Med. Sci., аssociate professor of the Department of internal medicine and medical rehabilitation of Novosibirsk State Medical University, Russia, 630084, Novosibirsk, Polzunov str., 21, tel. +7(383)279-99-45, e-mail: ok526@yandex.ru
GERASIMENKO OKSANA N., D. Med. Sci., professor of the Department of internal medicine and medical rehabilitation of Novosibirsk State Medical University, Russia, 630084, Novosibirsk, Polzunov str., 21, tel. +7(383)279-99-45, e-mail: mkb-2@yandex.ru
SHPAGIN ILIA S., C. Med. Sci., assistant of professor of the Department of internal medicine and medical rehabilitation of Novosibirsk State Medical University, Russia, 630084, Novosibirsk, Polzunov str., 21, tel. +7(383)279-99-45, e-mail: mkb-2@yandex.ru
SUROVENKO TATYANA N., D. Med. Sci., professor of the Department of pediatrics of Pacific State Medical University, Russia, 690002, Vladivostok, Ostryakov Ave., 2, tel. +7(423)242-97-78, e-mail: mkb-2@yandex.ru
KARMANOVSKAYA SVETLANA A., D. Med. Sci., assistant of professor of the Department of internal medicine and medical rehabilitation of Novosibirsk State Medical University, Russia, 630084, Novosibirsk, Polzunov str., 21, tel. +7(383)279-99-45, e-mail: mkb-2@yandex.ru
ERMAKOVA MARGARITA A., D. Med. Sci., associate professor of the Department of internal medicine of Medical University «REAVIZ», Russia, 107564, Moscow, Krasnobogatyrskaya str., 2, bld. 2, tel. +7(495)642-30-66, e-mail: mkb-2@yandex.ru
Abstract. Aim. Clinical and functional features, in ammation pattern and prognosis in occupational chronic obstructive pulmonary disease caused by gas or dust have been studied. Material and methods. It was a single center prospective observational study. Individuals with chronic obstructive pulmonary disease [GOLD 2011 criteria] exposed to gases (n=55) or dust (n=101) and tobacco smokers (n=103) have been enrolled. Control group contained healthy people (n=99). Follow up period was (4,9±0,25) years. Chronic obstructive pulmonary disease symptoms, exacerbations, lung functions (spirography, body plethysmography) and molecular components of the endotype (ELISA) were assessed. The analysis of survival by Kaplan — Meier and determination of predictors using Cox regression was carried out. In order to establish the effect of etiopathogenetic factor on the phenotype and endotype covariance analysis (ANCOVA) has been applied. Signi cance level was established as 0,05. Results and discussion. Chronic obstructive pulmonary disease from toxic gases was characterized by severity of clinical course, expressed by pulmonary hyperin ation, early development of pulmonary hypertension, and rare but severe exacerbations. For chronic obstructive pulmonary disease, the effects of inorganic dust were characterized by frequent light exacerbations, a moderate increase in pulmonary volumes in combination with pulmonary brosis. Overall 5-year survival was the lowest in the group of chronic obstructive pulmonary disease due to toxic gases — 81,8%. The main causes of death in patients with chronic obstructive pulmonary disease caused by toxic gases were pneumonia and cardiovascular diseases, from inorganic dust — pneumonia. According to multifactor analysis the predictors of unfavorable prognosis were exposure to toxic gases — work experience, serum concentration of VEGF A, PaO2, to inorganic dust — work experience, serum concentration of FGF 2, DLCO. Conclusion. Individual phenotypes of chronic obstructive pulmonary disease are developed in case of exposure to toxic gases or inorganic dust.
Key words: occupational chronic obstructive pulmonary disease, phenotype, endotype, exacerbations, survival analysis.
For reference: Shpagina LA, Kotova OS, Gerasimenko ON, Shpagin IS, Surovenko TN, Karmanovskaya SA, Ermakova MA. Phenotypes and endotypes of occupational chronic obstructive pulmonary disease caused by toxic gas or inorganic dust. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 56—65. DOI: 10.20969/VSKM.2017.10(5).56-65.
REFERENCES
1. Vasil’eva OS, Kravchenko NYu. Hronicheskaya obstruk- tivnaya bolezn’ legkih kak professional’noe zabolevanie: faktory riska i problema mediko-social’noj reabilitacii bol’nyh [The chronic obstructive disease of lungs as occu- pational illness: risk factors and problem of medical social rehabilitation of patients]. Rossijskij medicinskij zhurnal [Russian medical journal]. 2015; 21 (5): 22-26.
2. Serebryakov PV, Bakirov AB, Karimova LK, Rushkevich OP. Klinicheskie osobennosti zabolevanij organov dy- haniya i komorbidnoj patologii u rabotnikov promyshlen- nyh predpriyatij, sovershenstvovanie metodov pro laktiki i lecheniya [Clinical features of lung diseases and comorbid pathology in industry workers: improvement of prevention and treatment]. Ufa-Moskva: Federal’noe byudzhetnoe uchrezhdenie nauki «U mskij nauchno-issledovatel’skij institut mediciny truda i ehkologii cheloveka» [Ufa — Moscow : Federal budgetary institution of science «Ufa Research Institute of Occupational Health and Human Ecology]. 2016; 370 p.
3. Fishwick D, Sen D, Barber C et al. Occupational chronic obstructive pulmonary disease: a standard of care. Occup Med (Lond). 2015; 65: 270-282.
4. Chuchalin AG, Khaltaev N, Antonov NS et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963-974.
5. Abajobir AA, Abate KH, Abbafati C et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): 1211-1259.
6. Shpagina LA, Poteryaeva EL, Kotova OS et al. Aktual’nye problemy pul’monologii v sovremennoj profpatologicheskoj klinike [Current issues in occupational medicine]. Medicina truda i promyshlennaya ehkologiya [Occupational medicine and industrial ecology]. 2015; 9: 11-14.
7. Avdeev SN. Opredelenie klinicheskih fenotipov hronicheskoj obstruktivnoj bolezni legkih novyj podhod k terapii zabolevaniya [Determination of clinical phenotypes of chronic obstructive pulmonary disease a new treatment approach]. Terapevticheskij arhiv [Therapeutic archive]. 2011; 83 (3): 66-74.
8. Hurst JR, Vestbo J, Anzueto AN et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. Engl J Med. 2010; 363: 1128-1138.
9. Pascoe S, Locantore N, Dransfield MT et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled uticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3: 435- 442.
10. Hardin M, Silverman EK, Barr RG et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011; 12: 127.
11. Caillaud D, Lemoigne F, Carré P et al. Association between occupational exposure and the clinical characteristics of COPD. BMC Public Health. 2012; 12: 302.
12. Paulin LM, Diette GB, Blanc PD et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191: 557-565.
13. Rodríguez E, Ferrer J, Zock JP et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One. 2014; 9: e88426.
14. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017; http://www.goldcopd.com
15. Fomina VS, Kuz’mina LP. Ocenka soderzhaniya matrik- snyh metalloproteinaz (pro-MMP 1-1, MMP-2,8) i ih ingibitora (TIMP-1) u bol’nyh professional’nymi zabolevani- yami legkih [Evaluation of matrix metaloproteinases (pro- MMP-1, MMP-2,8) and their inhibitor (TIMP-1) contents in patients with occupational lung diseases]. Medicina truda i promyshlennaja ehkologiya [Occupational medicine and industrial ecology]. 2010; 7: 29–33.
16. Kanazawa H, Tochino Y, Asai K et al. Simultaneous assessment of hepatocyte growth factor and vascular endothelial growth factor in epithelial lining uid from patients with COPD. Chest. 2014; 146: 1159-1165.
17. Guzy RD, Li L, Smith CJ et al. Pulmonary brosis requires cell-autonomous mesenchymal broblast growth factor (FGF) signaling. Biol Chem. 2017; 292: 10364-10378.
18. Sogaard M, Madsen M, Lokke A et al. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis. 2016; 11: 455-465.
19. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33: 1165-1185. 20. Montani D, Laul EM, Descarga A et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J. 2015; 46: 1721–1731.
EPIDEMIOLOGY OF SARCOIDOSIS IN THE RUSSIAN FEDERATION
UDC 616-002.282-036.22(470+571)(048.8)
DOI: 10.20969/VSKM.2017.10(5).66-73
VIZEL ALEXANDER A., D. Med Sci., professor, Head of the Department of phthisiology and pulmonology of Kazan State Medical University, chief freelance pulmonologist of the Ministry of Health of Tatarstan, Russia, 420012, Kazan, Butlerov str., 49, e-mail: lordara@inbox.ru
VIZEL IRINA YU., C. Med. Sci., professor of Russian Academy of Natural History, assistant of professor of the Department of phthisiology and pulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, e-mail: tatpulmo@mail.ru
AMIROV NAIL B., D. Med. Sci., academician of Russian Academy of Natural History, professor of the Department general medical practice of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, e-mail: namirov@mail.ru
Abstract. Sarcoidosis is a systemic disease of immune system, characterized by formation of epithelioid cellular noncaseating granulomas and by immune paradox, manifested by excessive cellular reaction at the affected sites with peripheral anergy. Aim. This review is a summary of publications that contain information on the incidence, prevalence and clinical characteristics of sarcoidosis in different regions of the Russian Federation. Results and discussion. Analysis of publications on the epidemiology of sarcoidosis over the past 40 years has shown that, despite the heterogeneity of the data, there is a general tendency of increase in the incidence and prevalence of sarcoidosis. The prevalence of sarcoidosis was the highest in Karelia — 73 per 100 thousand population and the lowest — 8,2 per 100 thousand population in the Amur region. The epidemiology of sarcoidosis in the Russian Federation remains the subject of separate initiative studies. This determines the dependence of the results obtained on the activity and interest of doctors and researchers in each region, as well as on creation of «sarcoidosis centers». Conclusion. Epidemiology of sarcoidosis requires systematic approach and creation of a single federal register in order to obtain objective and comparable data. The increase in interest in idiopathic pulmonary brosis in recent years will possibly contribute to better detection and more accurate diagnosis of all interstitial and disseminated processes in the lungs.
Key words: sarcoidosis, incidence, prevalence, Russia.
For reference: Vizel АА, Vizel IYu, Amirov NB. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 66—73. DOI: 10.20969/VSKM.2017.10(5).66-73.
REFERENCES
1. Loke WS, Herbert C, Thomas PS. Sarcoidosis: Immuno- pathogenesis and immunological markers. Int J Chronic Dis. 2013; 2013: 928601.
2. Kluger N. Cutaneous complications related to tattoos: 31 cases from Finland. Dermatology. 2017; doi: 10.1159 / 000468536.
3. Ortiz Salvador JM, Victoria Martínez AM, Ferrer DS, Alegre de Miquel V, Pérez Ferriols A. Interferon alfa-induced sarcoidosis resolving without drug withdrawal. JAAD Case Rep. 2016; 2 (2): 146-149.
4. Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy? J Crohns Colitis. 2017; 11 (3): 378-383.
5. Díaz Del Arco C, Aceñero MJ. Sarcoid reaction: a rare occurrence associated with colon adenocarcinoma (case report and literature review). J Gastrointest Oncol. 2016; 7 (4): E72-76.
6. Roszkiewicz J, Smolewska E. Kaleidoscope of autoim- mune diseases in HIV infection. Rheumatol Int. 2016; 36 (11): 1481-1491.
7. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011; 183 (5): 573-581.
8. Vizel IYu, Vizel AA. Harakteristika registra bol’nyh sarkoidozom v Respublike Tatarstan [Characteristics of the register of patients with sarcoidosis in the Republic of Tatarstan]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary clinical medicine]. 2015; 8 (5): 18-26.
9. Raben AS. Sarkoidoz [Sarcoidosis]. Moskva [Moscw]: Medicina [Medicine]. 1964; 312 p.
10. Rabukhin AE, Dobrokhotova MN, Tonitrova NS. Sarkoidoz [Sarcoidosis]. Moskva [Moscw]: Medicina [Medicine]. 1975; 175 p.
11. Khomenko AG, Schweiger O ed. Sarkoidoz [Sarcoidosis]: SSSR–VNR [USSR-Hungary]. — Moskva [Moscw]: Medicina [Medicine]. 1982; 296 p.
12. Borisov SE. Sarkoidoz, kak biologicheskaja i medicinskaja problema [Sarcoidosis as a biological and medical problem]. Probl Tub. 2006; 4: 4-8.
13. Ozerova LV, Rybakova NP, Mikheeva LP. Dispansernoe nabljudenie bol’nyh sarkoidozom [Dispensary observation of patients with sarcoidosis]. Probl tub. 1998; 3: 24-27.
14. Garmash YuYu, Kolosovskaya VP. Vyjavlenie, zabolevae- most’, rasprostranennost’ sarkoidoza sredi naselenija Moskvy [Identi cation, incidence, prevalence of sarcoid- osis among the population of Moscow]. Tuberkuljoz segod- nja: Materialy VII rossijskogo s#ezda ftiziatrov [Tubercu- losis Today: Proceedings of the VII Russian Congress of Phthisiatricians]; Moskva: Izdatel’stvo BINOM [Moscow: Publishing House BINOM]. 2003; 342.
15. Rusakov NV, Mukhin NA, Brico NI et al. Osobennosti rasprostranenija sarkoidoza v uslovijah Moskvy [Features of the spread of sarcoidosis in Moscow conditions]. Gigiena i sanitarija [Hygiene and Sanitation]. 2012; 4: 16-18.
16. Greymer M, Kostina ZI. Organizacija dispansernogo nabljudenija za bol’nymi sarkoidozom organov dyhanija [The organization of dispensary observation of patients with sarcoidosis of respiratory organs]. Probl Tub. 1982; 4: 8-10.
17. Baranova OP, Ilkovich MM, Novikova LN et al. Osobennosti sovremennoj taktiki lechenija i dispansernogo nabljudenija bol’nyh sarkoidozom ljogkih [Features of modern tactics of treatment and dispensary observation of patients with pulmonary sarcoidosis]. Pul’monologija [Pulmonology]. 1998; XLVIII (1): 386.
18. Ilkovich MM, Abumuslimova EA, Grigorieva NO, Dzadzua DV. Ocenka kachestva diagnostiki intersticial’nyh zabolevanij legkih na ambulatornom jetape [Assessment of the quality of diagnosis of interstitial lung diseases at the outpatient stage]. Pul’monologija [Pulmonology]. 2006; 330: 92.
19. Baranova OP, Re tskaya NV, Stepanenko TA, Alexandrova NI, Popova SG. Jepidemiologija sarkoidoza organov dyhanija v Sankt-Peterburge (1998-2008) [Epidemiology of respiratory sarcoidosis in St. Petersburg (1998-2008)]. Sbornik trudov kongressa — XIX Nacional’nyj kongress po boleznjam organov dyhanija [Proceedings of Congress — XIX National Congress on Diseases of the Respiratory System]; Moskva: DizajnPress [Moscow: DesignPress]. 2009; 244: 216-217.
20. Tikhonovich EL, Vezikova NN, Varga OYu. Sarkoidoz v Respublike Karelija [Sarcoidosis in the Republic of Karelia]. Sbornik trudov kongressa — XXV Nacional’nyj kongress po boleznjam organov dyhanija [Proceedings of the Congress — XXV National Congress on Diseases of the Respiratory System]; Moskva: DizajnPress [Moscow: DesignPress]. 2015; 235: 200.
21. Smirnova MS, Soloviev KI, Berezhonova SG. Raspros- tranennost’ sarkoidoza v Novgorodskoj oblasti [The prevalence of sarcoidosis in the Novgorod region]. Sbornik trudov kongressa — XXV Nacional’nyj kongress po bolezn- jam organov dyhanija [Proceedings of the Congress — XXV National Congress on Diseases of the Respiratory System]; Moskva: DizajnPress [Moscow: DesignPress]. 2015; 236: 201.
22. Oblogina LI, Nazarycheva RA, Bykova NN et al. Sarkoidoz organov dyhanija: jepidemiologija, klinika, techenie [Sarcoidosis of the respiratory organs: epidemiology, clinic, course]. Pul’monologija [Pulmonology]. 2000; 445: 122.
23. Chistyakova NG, Lomachenkov VD. Sarkoidoz v Smolenskoj oblasti [Sarcoidosis in the Smolensk region]. Probl. 1995; 1: 58.
24. Listopadova MV. Sovershenstvovanie monitoringa bol’nyh sarkoidozom v uslovijah ambulatorno-stacionarnogo nabljudenija [Perfection of monitoring of patients with sarcoidosis in conditions of ambulatory-stationary observation]. Moskva [Moscow]. 2015; 24 p.
25. Tyukhtin NS, Ushakova MF, Stogova NA, Grishaeva LN. Dispansernoe nabljudenie bol’nyh sarkoidozom [Dispensary observation of patients with sarcoidosis]. Nauchno-medicinskij vestnik Central’nogo Chernozem’ja [Scienti c and Medical Herald of the Central Chernozem Region]. 2002; 10: 14-18.
26. Kibrik BS, Zhiltsova AV, Timachev VP, Tikhomirova LM. Vyjavljaemost’ bol’nyh sarkoidozom organov dyhanija i nekotorye dannye nabljudenija [Detection of patients with sarcoidosis of respiratory organs and some observational data]. Differencial’naja diagnostika sarkoidoza i tuber- kuleza legkih [Differential diagnosis of sarcoidosis and pulmonary tuberculosis]. Moskva [Moscow]. 1988; 11-13.
27. Borisov SE. Sarkoidoz organov dyhanija (jepidemiologija, klinika, diagnostika i lechenie) [Sarcoidosis of the respiratory organs (epidemiology, clinic, diagnosis and treatment)]. Moskva [Moscow]. 1995; 42 p.
28. Borisova SB, Vasilieva NV, Shprykov AS. 15-letnij opyt nabljudenija bol’nyh sarkoidozom organov dyhanija [15-year experience of observation of patients with respiratory sarcoidosis]. Tuberkuljoz i bolezni ljogkih [Tuberculosis and lung diseases]. 2011; 4: 61.
29. Postnikova LB, Gudim AL, Boldina MV, Korotaeva LA, Abanin AM. Klinicheskie projavlenija, aspekty diagnostiki i lechenija sarkoidoza legkih v uslovijah Nizhnego Novgoroda [Clinical manifestations, aspects of diagnosis and treatment of pulmonary sarcoidosis in the conditions of Nizhny Novgorod]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of contemporary clinical medicine]. 2016; 9 (4): 44-51.
30. Slepova RI, Arkhipov MI, Kazakova VI. Differencial’naja diagnostika ljogochnyh disseminacij [Differential diagnosis of pulmonary dissemination]. Kazanskij medicinskiy zhurnal [Kazan medical journal]. 1982; 63 (2): 29-31.
31. Nasretdinova GR. Osobennosti klinicheskih projavlenij sarkoidoza v Respublike Tatarstan [Features of clinical manifestations of sarcoidosis in the Republic of Tatarstan]. Moskva [Moscow]. 2005; 167 p.
32. Vizel IYu, Vizel AA. Harakteristika registra bol’nyh sarkoidozom v Respublike Tatarstan [Characteristics of the register of patients with sarcoidosis in the Republic of Tatarstan]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of contemporary clinical medicine]. 2015; 8 (5): 18-26.
33. Melkumov GA, Aminev KhK, Atalipova IN. Diagnostika i lechenie sarkoidoza organov dyhanija v Bashkirskoj ASSR [Diagnostics and treatment of respiratory sarcoidosis in the Bashkir ASSR]. Differencial’naja diagnostika sarkoidoza i tuberkuleza legkih [Differential diagnosis of sarcoidosis and pulmonary tuberculosis]. Moskva [Moscow]. 1988; 59-62.
34. Amineva LKh. Diagnostika, lechenie i dispansernoe nabljudenie bol’nyh sarkoidozom [Diagnosis, treatment and dispensary observation of patients with sarcoidosis]. Ufa. 1999; 26 p.
35. Bogdanova YuV, Mischenko OV, Artamonov ID et al. Problemy diagnostiki i lechenija sarkoidoza v Samarskoj oblasti [Problems of diagnosis and treatment of sarcoidosis in the Samara region]. Prakticheskaja medicina [Practical medicine]. 2004; 2 (7): 34-35.
36. Bashaeva ZR, Salikova NA, Mezhebovsky AV, Mezhe- bovsky VR. Zabolevaemost’ sarkoidozom v Orenburgskoj oblasti [The incidence of sarcoidosis in the Orenburg region]. Sbornik trudov XVII Nacional’nogo Kongressa po boleznjam organov dyhanija [Works of the XVII National Congress on Diseases of the Respiratory System]. 2007; 390: 219.
37. Mezhebovsky VR, Mezhebovsky AV, Salikova NA. Osobennosti projavlenija sarkoidoza sredi naselenija gorodov i sel’skoj mestnosti Juzhnogo Urala [Features of the manifestation of sarcoidosis among the population of cities and rural areas of the Southern Urals]. Orenburgskij medicinskij vestnik [Orenburg Medical Journal]. 2014; 2 (4:8): 70-74.
38. Teryaeva MV, Ikonnikova SI, Militsina M et al. Sar- koidoz v Ekaterinburge [Sarcoidosis in Yekaterinburg]. Pul’monologija 2003: XIII Nacional’nyj kongress po bo- leznjam organov dyhanija: Sankt-Peterburg [Pulmonology 2003: XIII National Congress on Respiratory Diseases: St. Petersburg]. 2003; 249.
39. Nesterovsky YaI, Kostenko AD. Nekotorye itogi raboty po diagnostike i lecheniju bol’nyh sarkoidozom [Some results of the work on the diagnosis and treatment of patients with sarcoidosis]. Differencial’naja diagnostika sarkoidoza i tuberkuleza legkih [Differential diagnosis of sarcoidosis and pulmonary tuberculosis]. Moskva [Moscow]. 1988; 77-79.
40. Petrov DV, Ovsyannikov NV, Konenko AYu, Pyiannikova NG, Kapustian OV, Kapralov EA, Bunova SS, Gasanenko LN. Rezul’taty vnedrenija «Porjadka okazanija medicinskoj pomoshhi bol’nym sarkoidozom» v gorode Omske [Results of the introduction of the “Order of medical care for patients with sarcoidosis” in the city of Omsk]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of contemporary clinical medicine]. 2013; 6 (2): 42-46.
41. Victorova IB, Khanin AL, Kulikov YuV et al. Struktura disseminirovannyh zabolevanij legkih v Kemerovskoj oblasti [Structure of disseminated lung diseases in the Kemerovo Region]. Jeffektivnost’ protivotuberkuleznyh meroprijatij [Effectiveness of antituberculous activities]. Kemerovo. 2005; 25-26.
42. Denisova OA, Ustyuzhanina EA, Chernogoryuk GE, Lenskaya LG, Chernyavskaya GM, Podoksenova NV, Topolnitsky EB. Opyt organizacii medicinskoj pomoshhi bol’nym sarkoidozom v Tomskoj oblasti [Experience in the organization of medical care for patients with sarcoidosis in the Tomsk region]. Sbornik trudov kongressa — XXII Nacional’nyj kongress po boleznjam organov dyhanija: DizajnPres [Collected Works of Congress — XXII National Congress on Diseases of the Respiratory System: DesignPress]. 2012; 236.
43. Lenshin AV, Grebennik AG, Suslova YuV, Karakulova OA. Vnutrigrudnoj sarkoidoz: Optimizacija ambulatorno- poliklinicheskoj luchevoj diagnostiki [Intra thoracic sarcoidosis: Optimization of ambulatory polyclinic radiation diagnosis]. Zdorov’e: Medicinskaja jekologija: Nauka [Health: Medical ecology: The science]. 2009; 39-40 (4- 5): 105-108.
44. Antipushina DN, Zaitsev AA. Sarkoidoz organov dyhanija u voennosluzhashhih [Sarcoidosis of the respiratory system of military personnel]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of contemporary clinical medicine]. 2015; 8 (3): 7-11.
INTERNATIONAL COOPERATION OF PEOPLE’S COMMISSARIAT OF HEALTH OF THE RSFSR IN 1920—1930
UDC 614.2(47+57):001.83(100)(091)
DOI: 10.20969/VSKM.2017.10(5).74-78
PODDUBNY MIKHAIL V., C. Med. Sci., Head of sector of the Department of history of medicine and public health of N.A. Semashko National Scientific Research Institute of Public Health, Russia, 105064, Moscow, Vorontsovo Pole str., 12, bld. 1, e-mail: mihail.poddubny@yandex.ru
EGORYSHEVA IRINA V., C. Hist. Sci., leading researcher of the Department of history of medicine and public health of N.A. Semashko National Scientific Research Institute of Public Health, Russia, 105064, Moscow, Vorontsovo Pole str., 12, bld. 1, e-mail: egorysheva@rambler.ru
MOROZOV ALEXEY V., C. Med. Sci., senior researcher of the Department of history of medicine and public health of N.A. Semashko National Scientific Research Institute of Public Health, Russia, 105064, Moscow, Vorontsovo Pole str., 12, bld. 1, e-mail: А0067138@yandex.ru
Abstract. Aim. The objective of the study is to demonstrate how the system of international cooperation with international organizations such as League of Nations, Red Cross, in the eld of medicine has been developed in Soviet Russia. Material and methods. General methodological approaches to historical and medical research with the use of problem- chronological method of system analysis have been applied. Results and discussion. Since the 2nd half of the XIX century Russian doctors have been actively participating in various international forums and conferences. Thus, in the early XX century Russia has already obtained experience of international cooperation in the eld of health. After the Soviet power found itself in a dif cult economic and political blockade, development of international scienti c connections has been adversely affected. The article describes attempts of the Soviet government to organize international cooperation in the area of medicine and sanitation escaping from international isolation, as well as participation of Soviet scientists and representatives of the national health Committee in international meetings organized by the League of Nations. Conclusion. International cooperation of Soviet Russia in the elds of medicine and sanitation allowed the young republic to escape international isolation and to conclude favorable sanitary agreements with neighboring countries. The leading foreign specialists in the eld of medicine and sanitation have been invited to the country as a result of international collaboration.
Key words: international cooperation, sanitary agreement, Soviet Russia, Red Cross, the League of Nations.
For reference: Poddubny MV, Egorysheva IV, Morozov AV. International cooperation of people’s commissariat of health of the RSFSR in 1920 — 1930. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 74—78. DOI: 10.20969/ VSKM.2017.10(5).74-78.
REFERENCES
1. Fetisov NN, Furgal SM, Zhilyaeva EP. Mezhdunarodnoe sotrudnichestvo [International cooperation]. Zdravoohrane- nie Rossii ХХ vek [Health Russia of the twentieth century]. Moskva [Moscow]. 2001; 291-292.
2. Poddubnyj MV. Ehkspediciya v tragediyu [The expedition into a tragedy]. Rodina [Homeland]. 1998; 1: 78–80.
3. Egorysheva IV, Danilishina EI. Iz istorii mezhdunarodnogo sotrudnichestva [From the history of international cooperation]. Moskva: Materialy 1 s»ezda konfederacii istorikov mediciny [Moscow: Materials of the 1st Congress of the Confederation of historians of medicine]. 1998; 220-221.
4. Semashko NA ed. Pyat’ let sovetskoj mediciny: 1918-1923 [Five years of Soviet medicine: 1918-1923]. Moskva: Izdatel’stvo Narkomzdrava RSFSR [Moscow: Publishing house of the People’s Commissariat of Education of the RSFSR]. 1923; 33-34.
5. Gosudarstvennyj arhiv Rossijskoj Federacii [State Archives of the Russian Federation]. Fond [fund] 482. Opis’ [inventory] 35. Delo [business] 125. List [sheet] 361–369.
6. Rosenfeld G. Sowietunion und Deutschland 1922-1933 [Sowietunion und Deutschland 1922-1933]. Koln: Pahl- Rugenstein. 1984; 512 p.
7. Gosudarstvennyj arhiv Rossijskoj Federacii [State Archives of the Russian Federation]. Fond [fund] 482. Opis’ [inventory] 35. Delo [business] 173. List [sheet] 111.
8. Gosudarstvennyj arhiv Rossijskoj Federacii [State Archives of the Russian Federation]. Fond [fund] 482. Opis’ [inventory] 35. Delo [business] 58. List [sheet] 253.
9. Sysin AN. Pamyati NG Frejberga [Memory NG Freiberga]. Gigiena i ehpidemiologiya [Hygiene and epidemiology]. 1927; 9: 127-128.
10. Semashko NA ed. Byulleten’ Narkomzdrava RSFSR [Bulletin of people’s Commissariat of the RSFSR]. Moskva: Izdatel’stvo Narkomzdrava RSFSR [Moscow: Publishing house of the People’s Commissariat of Education of the RSFSR]. 1927; 14: 3-5.
11. Frenkel’ ZG. Zapiski i vospominaniya o projdennom zhiznennom puti [Notes and memories of a passed life’s journey]. SPb: Nestor-Istorija [St Petersburg: Nestor- History]. 2009; 365-374, 379-380.
12. Poddubnyj MV. Inostrannye vrachi o sovetskoj medicine 1930-h godov [Foreign doctors about Soviet medicine 1930th years]. Sovetskoe zdravoohranenie [The Soviet health care]. 1991; 2: 72–75.
THE RATIONALE OF QUESTIONNAIRE APPLICATION IN PHYSICIANS AND PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE FOR EARLY DETECTION OF EXACERBATIONS (conclusion of the council of experts of Volga, Central and Southern federal districts of Russia)
UDC 616.24-036.12-036.65-071.1:303.62
DOI: 10.20969/VSKM.2017.10(5).79-89
OVCHARENKO SVETLANA I., D. Med. Sci., professor of the Department of internal medicine No 1 of I.M. Sechenov First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8, bld. 2, tel. 8(499)248-45-23,
e-mail: svetftk@mail.ru
VIZEL ALEXANDER A., D. Med. Sci., professor, Head of the Department of phthisiology and pulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. (9872) 96-25-99, e-mail: lordara@inbox.ru
GAMOVA INNA V., C. Med. Sci., associate professor of the Department of allergology and immunology of V.I. Razumovskiy Saratov State Medical University, Russia, 410012, Saratov, Bol. Kazach’ya str., 112, tel. (9033) 28-50-69, e-mail: innapris@yandex.ru
DOBROTINA IRINA S., C. Med. Sci., associate professor of the Department of internal medicine of V.G. Vogralik Nizhniy Novgorod State Medical Academy, Russia, 603005, Nizhniy Novgorod, Minin i Pozharsky sq. 10/1, tel. (8314) 39-09-43, e-mail: dobrotina@mail.ru
ZHESTKOV ALEXANDER V., D. Med. Sci., professor, Head of the Department of microbiology, immunology and allergology, Samara State Medical University, Russia, 443099, Samara, Chapaevskaya str., 89, tel. (8462) 60-33-61, e-mail: avzhestkov2015@yandex.ru
POSTNIKOVA LARISA B., D. Med. Sci., professor of the Department of internal medicine of Nizhniy Novgorod City Clinical Hospital No 38, Russia, 603000, Nizhniy Novgorod, Chernyshevskiy str., 22, tel. (9103) 90-64-37, e-mail: plbreath@mail.ru
PROZOROVA GALINA G., D. Med. Sci., professor of the Department of general medical practice (family medicine) of Institute of additional education of N. Burdenko Voronezh State Medical University, Russia, 394036, Voronezh, Studencheskaya str., 10, tel. (4732) 59-38-05, e-mail: prozorovagg@gmail.com
KHAMITOV RUSTEM F., D. Med. Sci., professor, Head of the Department of internal medicine No 2 of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. (9172) 72-96-72, e-mail: rhamitov@mail.ru
UKHANOVA OLGA P., D. Med. Sci., professor of the Department of immunology of Stavropol State Medical University, Russia, 355017, Stavropol, Mir str., 310, tel. (9288) 18-91-76, e-mail: uhanova_1976@mail.ru
SHABANOV EVGENIY A., C. Med. Sci., assistant of professor of the Department of internal medicine of Kursk State Medical University, Russia, 305004, Kursk, Karl Marx str., 3, tel. (9102) 10-76-38, e-mail: dr.ev-geniy85@mail.ru
Abstract. Aim. Draft questionnaires for doctors and lea ets for patients acceptable according to the experts in the eld of respiratory medicine of 3 federal districts of Russia have been introduced in order to create national instruments for diagnosis of chronic obstructive pulmonary disease exacerbations. Material and methods. The meeting of experts was held within the council with presentation and discussion of questionnaires for doctors and patient materials aiming to identify exacerbations of chronic obstructive pulmonary disease with subsequent agreement on the projects. Results and discussion. The scale of dyspnea, cough and sputum (BCSS) should be considered as a simple, highly sensitive and speci c tool for determining the current state of health in chronic obstructive pulmonary disease in clinical practice. Improving the diagnosis of retrospective exacerbations of chronic obstructive pulmonary disease is possible with the use of a number of questions by doctors, specifying the rate of transferred hospitalizations, courses of antibiotic therapy, systemic glucocorticosteroid intake due to impairment of respiratory symptoms, etc. Objecti cation of data on the frequency of exacerbations, including unreported ones, in the practice of pulmonologist is possible using an original complex instrument based on indirect signs of the chronic obstructive pulmonary disease phenotype with frequent exacerbations. An optimal version of the material that can in uence the increase in the number of chronic obstructive pulmonary disease exacerbations reports is a lea et for patients with a plan of action in case of the exacerbation. Conclusion. The recommended versions of the questionnaires and the lea et for patients will act as the basis for consideration and development of national tools aimed at improving diagnosis of exacerbations of chronic obstructive pulmonary disease in real clinical practice.
Key words: chronic obstructive pulmonary disease, COPD, exacerbations, questionnaires, material for the patient.
For reference: Ovcharenko SI, Vizel AA, Gamova IV, Dobrotina IS, Zhestkov AV, Postnikova LB, Prozorova GG, Khamitov RF, Ukhanova OP, Shabanov EA. The rationale of questionnaire application in physicians and patients with chronic obstructive pulmonary disease for early detection of exacerbations (сonclusion of the council of experts of Volga, Central and Southern federal districts of Russia). The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 79—89. DOI: 10.20969/VSKM.2017.10(5).79-89.
REFERENCES
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD). 2017; 123 p. http://goldcopd.org/wp-content/ uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
2. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J RespirCrit Care Med. 2004; 169: 1298– 1303.
3. Agusti A et al. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. J COPD F. 2014; 1 (2): 166-184.
4. Аrhipov VV, Arhipova DE, Stukalina EJu, Lazarev AA. Chastota vstrechaemosti otdel’nyh fenotipov hronicheskoj obstruktivnoj bolezni legkih v Rossijskoj Federacii, ih harakteristiki i podhody k lecheniju [Frequency of occurrence of individual phenotypes of chronic obstructive pulmonary disease in the Russian Federation, their characteristics and approaches to treatment]. Prakticheskaja pul’monologija [Practical pulmonology]. 2016; 3: 20-25.
5. Оvakimjan KV, Kuznecova OJu, Pohaznikova MA. Rol’ oprosnikov dlja vyjavlenija respiratornyh simptomov v rannej diagnostike hronicheskoj obstruktivnoj bolezni legkih i bronhial’noj astmy [The role of questionnaires to identify respiratory symptoms in the early diagnosis of chronic obstructive pulmonary disease and bronchial asthma]. Rossijskij semejnyj vrach [Russian family doctor]. 2013; 2 (17): 10 -17.
6. Draft quali cation opinion of quali cation of exacerbations 5 of chronic pulmonary disease tool (EXACT), and EXACT-6 respiratory symptoms measure (E-RS) for evaluating treatment outcomes in clinical trials in COPD. 2015; http://www.ema.europa.eu/docs/en_GB/document_ library/Regulatory_and_procedural_guideline/2015/04/ WC500185442.pdf
7. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012; 67: 970–976.
8. Roche N, Chavaillon J-M, Maurer C, Zureik M, Piquet J. A clinical in-hospital prognostic score for acute exacerbations of COPD. Respiratory Research. 2014; 15: 99-107.
9. Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A. A Score to Predict Short-Term Risk of COPD Exacerbations (SCOPEX). Int J COPD. 2015; 10: 201–209.
10. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest. 2003; 124: 2182 — 2191.
11. DeVries R, Kriebel D, Sama S. Validation of the breathlessness, cough and sputum scaleto predict COPD exacerbation. Prim Care Respir Med. 2016; 26: 160-183.
12. Leidy NK, Wilcox TK, Jones PW et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value in health; ISPOR. 2010; 13 (8): 965-975.
13. Michele L, McCarroll ML, Pohle-Krauza RJ, Volsko TA, Martin JL, Krauza ML. Use of the Breathlessness, pdf Cough, and Sputum Scale (BCSS©) in Pulmonary Rehabilitation. Respir Med J. 2013; 7: 1-5.
14. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and rst validation of the COPD Assessment Test. Eur Respir J 2009; 34 (3): 648-654.15. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960; 2: 1662.
16. Kessler R, Ståhl E, Vogelmeier C, Haughney J, Trudeau E, Löfdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006; 130: 133–142.
17. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 1998; 157: 1418-1422.
18. Williams V, HardingeM, Ryan S, Farmer A. Patients’ experience of identifying and managing exacerbations in COPD: a qualitative study. Primary Care Respiratory Medicine. 2014; 24: 14062.
19. Barnes N, Calverley PM, Kaplan A, Rabe KF. Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med. 2013; 13: 54.
20. COPD Foundation Inc (US). Staying Healthy and Avoiding Exacerbations. http://www.copdfoundation.org/What-is- COPD/Living-with-COPD/Staying-Healthy-and-Avoiding- Exacerbations.aspx
21. Lung Disease & Respiratory Health. http://www.webmd. com/lung/10-signs-copd-exacerbation
22. COPD Exacerbations. http://www.healthline.com/health/ copd/exacerbation-symptoms-and-warning-signs#see- a-doctor3
23. American Lung Association. My COPD Action Plan. http:// www.lung.org/assets/documents/copd/copd-action-plan.
24. Howcroft M, Walters EH, Wood-Baker R, Walters JAE. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2016; 12: CD005074. DOI: 10.1002/14651858.CD005074.pub4.
